Skip to main content
SpringerLink
Log in

Exenatide in T2DM in Spain: better outcomes, lower cost

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The study was funded by AstraZeneca Spain.

Reference

  • Capel M, et al. Cost-Effectiveness Analysis of Exenatide versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus. PharmacoEconomics-Open : 23 Jul 2019. Available from: URL: https://doi.org/10.1007/s41669-019-0171-y

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Exenatide in T2DM in Spain: better outcomes, lower cost. PharmacoEcon Outcomes News 834, 19 (2019). https://doi.org/10.1007/s40274-019-6119-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-019-6119-8

Search

Navigation